TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01450137
Drug: Tocilizumab + Glucocorticoids (GCs)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 8mg/kg every 4 weeks until week 52.
Study: NCT04037085
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
Study: NCT03067441
Drug: bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bempedoic acid 180 mg tablets taken orally, once per day.
Study: NCT03968146
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
Study: NCT03968146
Drug: rescue Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
Study: NCT03968146
Drug: pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
Study: NCT02936895
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D at a dose of 50,000 IU per day for 2 days
Study: NCT02838030
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 gr per day
Study: NCT04140305
Drug: RPC-1063
Normalized name: olipudase alfa-rpcp
DrugBank: Olipudase alfa (DB12835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00705510
Drug: 0.05% cyclosporin eye drop
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use the medication twice daily for 3 months
Study: NCT00982722
Drug: calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Study: NCT01165008
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00256555
Drug: Nutropin AQ
Normalized name: Nutropin AQ
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00156078
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03504033
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation to maintain anesthesia
Study: NCT03504033
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalation to maintain anesthesia
Study: NCT05115318
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
Study: NCT02035384
Drug: turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
Study: NCT01318902
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules.
Study: NCT01318902
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets.
Study: NCT03004287
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
Study: NCT03004287
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth at bedtime: days 1-4 of Induction
Study: NCT03115255
Drug: intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
Study: NCT03004287
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
Study: NCT03004287
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
Study: NCT03004287
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study: NCT03004287
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study: NCT03004287
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study: NCT03004287
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein: days -4 - -1 of Transplant(s)
Study: NCT03004287
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
Study: NCT03004287
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
Study: NCT00833859
Drug: GTX (gemcitabine, docetaxel and capecitabine)
Normalized name: toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
Study: NCT02991612
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive Rifaximin 400mg bid for 2 months
Study: NCT03004846
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be supplied as white to off-white vehicle ointment for topical application.
Study: NCT03556696
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
Study: NCT02464319
Drug: hrIL-2 active
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
Study: NCT00408681
Drug: lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03163238
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
Study: NCT01264003
Drug: sefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In prophylaxis
Study: NCT03858582
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab 200mg
Study: NCT03731715
Drug: Carisbamate
Normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
Study: NCT03048448
Drug: Fevipiprant
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 450mg dose
Study: NCT00479362
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin is either interrupted or uninterrupted prior to device implantation
Study: NCT00479362
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin is continued without interruption prior to device implantation
Study: NCT02163369
Drug: Peppermint and Lavender Essential Oils
Normalized name: Lavender oil
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630032
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m² every 3 weeks
Study: NCT00630032
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m² every 3 weeks
Study: NCT00630032
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m² every 3 weeks
Study: NCT00870493
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 300 mg daily oral
Study: NCT02449564
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus 1mg daily
Study: NCT02798523
Drug: Methylprednisolone sodium succinate(Solu-Medrol)
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried.
Study: NCT02489630
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1mg/kg ketamine IV
Study: NCT00025649
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025649
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025649
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025649
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00025649
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02234011
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01125891
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
Study: NCT00629824
Drug: pegylated interferon alpha and plus ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
Study: NCT00629824
Drug: pegylated interferon alpha and plus ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
Study: NCT01821677
Drug: Danazol Capsules
Normalized name: Danazol Capsules
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00538733
Drug: thalomid
Normalized name: Thalomid
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)
Study: NCT00538733
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle
Study: NCT00538733
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)
Study: NCT04036617
Drug: NaQuinate
Normalized name: quinate
DrugBank: Decoquinate (DB11394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
Study: NCT01377467
Drug: Denosumab (Prolia)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg s.c. injection at baseline and after 6 months
Study: NCT04439578
Drug: SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampicin was administered in the morning.
Study: NCT01613105
Drug: Acarbose (Precose/Glucobay, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
Study: NCT04283877
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 x 10 mg oral tablets. Single acute dose for all participants
Study: NCT03654547
Drug: TT-00420
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg.
Study: NCT02032524
Drug: Avalglucosidase Alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
Study: NCT00792766
Drug: everolimus (RAD001)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
Study: NCT01982201
Drug: Lesinurad 400 mg
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01982201
Drug: MINTOX 10 mL
Normalized name: Mintox
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507246
Drug: IV morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
Study: NCT01507246
Drug: EXPAREL (bupivacaine liposome injectable suspension)
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study: NCT02037126
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
Study: NCT02037126
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug will be used as the control. Diphenhydramine is a histamine blocker.
Study: NCT01589094
Drug: Gemcitabine and Cisplatin (DD GC)
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
Study: NCT04553887
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single agent, 110mg p.o once daily until disease progressed
Study: NCT03545516
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of bupivacaine into the surgical incision prior to its closure.
Study: NCT03545516
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
Study: NCT00539344
Drug: ANG1005
Normalized name: ANG1005
DrugBank: ANG1005 (DB18167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion once every 21 days
Study: NCT01056107
Drug: ROSE-010
Normalized name: Rose Oil
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
Study: NCT00920309
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
Study: NCT02420652
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02420652
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05671900
Drug: Gemcitabine 1000 mg, Docetaxel 37.5g
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
Study: NCT03270787
Drug: Compound danshen dripping pills
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
Study: NCT02981472
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT00080210
Drug: Puricase
Normalized name: Puricase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00335712
Drug: ONO-5129
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04555213
Drug: NOX66
Normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NOX66 Suppository